A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
Conditions: Recurrent Ovarian Cancer; Folate Receptor-Alpha Positive Interventions: Drug: Mirvetuximab Soravtansine; Drug: Lubricating Eye Drops; Drug: Prednisolone acetate ophthalmic suspension 1% eye drops; Drug: Brimonidine tartrate ophthalmic solution eye drops Sponsors: ImmunoGen, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Sublingual Atropine Bioequivalence by Route of Administration (SABER)
Conditions: Atropine Bioequivalence Interventions: Drug: Atropine Sulfate Ophthalmic Solution USP, 1%; Drug: Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL) Sponsors: Biomedical Advanced Research and Development Authority; Rho Federal Systems Division, Inc.; Allucent Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
The Safety and Efficacy Study of Ethylenediaminetetraacetic Acid (EDTA) Ophthalmic Solution in Patients With Loss of Contrast Sensitivity Due to Age-Related, Low-Grade Nuclear Cataract
Conditions: Age Related Cataracts Interventions: Drug: EDTA Ophthalmic Solution 2.6%; Drug: EDTA Ophthalmic Solution 1.3%; Drug: Saline Solution (Placebo) Sponsors: Livionex Inc. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Study to Evaluate the Safety and Tolerability of PRO-231 Ophthalmic Solution Versus VIGAMOXI ® on the Ocular Surface of Healthy Subjects.
Conditions: Ophthalmological Agent Toxicity Interventions: Drug: PRO-231; Drug: VIGAMOXI ® Sponsors: Laboratorios Sophia S.A de C.V. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease
Conditions: Dry Eye Interventions: Drug: VVN001 Ophthalmic Solution, 5%; Drug: VVN001 Ophthalmic Solution, Vehicle Sponsors: VivaVision Biotech, Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Distraction Techniques in Periocular Anesthesia: Tapping vs Vibration
Conditions: Anesthetics, Local; Blepharoplasty; Age-Related Ptosis; Adult; Humans; Lidocaine; Ophthalmologic Surgical Procedure; Vibration; Surgery Interventions: Device: Vibration Sponsors: University of Manitoba; Winnipeg Regional Health Authority Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Barcelona Esquerra Glaucoma Artificial Intelligence-based Screening Program (BEGAS)
Conditions: Glaucoma Interventions: Diagnostic Test: Software analysis; Diagnostic Test: Ophthalmologist examination Sponsors: Hospital Clinic of Barcelona Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Understanding Visual Processing After Occipital Stroke
Conditions: Vision Loss Partial; Vision; Loss, Both Eyes; Hemianopia, Homonymous; Hemianopia; Quadrantanopia; Stroke, Ischemic; Stroke - Occipital Infarction; Cortical Blindness; Occipital Lobe Infarct; Peripheral Visual Field Defect of Both Eyes Sponsors: University of Rochester Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials
Phase I Clinical Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.
Conditions: Healthy Interventions: Drug: PRO-232; Other: Placebo Sponsors: Laboratorios Sophia S.A de C.V. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials
Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.
Conditions: Healthy Interventions: Drug: PRO-232; Other: Placebo Sponsors: Laboratorios Sophia S.A de C.V. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials
Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances
Conditions: Mesopic Vision; Night Vision Loss Interventions: Drug: phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist; Drug: Placebo Sponsors: Ocuphire Pharma, Inc.; Viatris Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
To Evaluate the Consistency and Repeatability of Portable Automatic Optometry 2-WINS for Cycloplegic Optometry in Adolescents and Children
Conditions: Optometry Sponsors: He Eye Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT
Conditions: Ocular Graft-versus-host Disease Interventions: Drug: Cyclosporine ophthalmic solution 0.1%; Drug: Tacrolimus ophthalmic ointment 0.03% Sponsors: Hospital Universitario Dr. Jose E. Gonzalez Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
Robotic Subretinal tPA Injection Study
Conditions: Subretinal Hemorrhage; Age-Related Macular Degeneration Interventions: Device: Robotic subretinal tPA injection Sponsors: Universitaire Ziekenhuizen KU Leuven; DORC Dutch Ophthalmic Research Center International BV Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
iReach: a Rehabilitative Medical Device
Conditions: Blindness; Visual Impairment Interventions: Device: iReach Sponsors: Istituto Italiano di Tecnologia Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials
